bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.03.22.644772

A common network of residue-residue contacts underlies peptides' interactions with MHC class II complex

Abstract

The formation of a stable peptide-MHC class II complex is a critical step in the adaptive immune response. In this work, we investigate the residue-residue contacts that anchor the peptide between the alpha and beta chains of MHC II and examine whether such anchoring residue-residue contacts are shared among different peptide-MHC II complexes. We hypothesize that there is a similarity between the map of contacts of antigenic peptides with the alpha and beta chains of MHC II and the map of contacts of the "natural" complex of MHC II with the CLIP - the fragment of the gamma chain. Thus, the CLIP-MHC II complex - specifically, PDB structure 3PDO - was taken as the prototype for peptide-MHC II interaction. To compare the contact maps between the prototype structure and antigenic peptides/MHC II in 14 crystal structures, we developed a unified numbering system for residues in peptide-MHC II complexes. Using this unified residue numbering system, we show that approximately half of the CLIP-MHC II residue-residue contacts have analogs in structures that involve different antigenic peptides and different MHC II (HLA-DR, HLA-DQ, and mouse A/B) alpha and beta chains. We present here this common network of contacts that underlies peptide/MHC class II interactions, as well as the structural and physicochemical characteristics of these contacts. Based on these shared characteristics, we propose criteria for the specificity of antigenic peptide loading into MHC II, whereby one can predict whether a particular peptide fragment will bind to MHC II as well as the likely localization of the fragment within the peptide binding groove of MHC II.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kister, A. E., Kister, I.. 2025-03-25. A common network of residue-residue contacts underlies peptides' interactions with MHC class II complex. https://doi.org/10.1101/2025.03.22.644772

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗